Neurocrine Biosciences | NBIX - 営業経費

株価
131.25
毎日の変更
3.13 2.44%
毎月
1.97%
毎年
21.88%
Q2 予測
124.95




営業経費 変化する 日付
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Prothena USD 27.23M 14.95M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Repligen USD 177.94M 1.82M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xoma USD 22.84M 1.67M 2024-09